摘要
目的系统评价脑心通胶囊联合他汀类药物治疗高脂血症的疗效和安全性。方法计算机检索Cochrane图书馆、Pub Med、Embase、Medline、CNKI、CBM、VIP、万方等数据库,纳入相关随机对照研究(RCT),并进行评价,采用Revman5.3软件分析数据。结果纳入14篇RCTs,共1 244例受试者。相比单独使用他汀类药物,脑心通联合他汀类药物的血脂总疗效提高[RR=1.20,95%CI(1.10,1.31),P<0.000 1]。治疗后总胆固醇水平低于对照组[WMD=-0.79,95%CI(-1.06,-0.53),P<0.000 01],其中联合阿托伐他汀钙亚组异质性较低(P=0.09,I2=48%)。治疗后甘油三酯水平低于对照组[WMD=-0.68,95%CI(-0.92,-0.45),P<0.000 01]。治疗后高密度脂蛋白高于对照组[WMD=0.28,95%CI(0.18,0.37),P=0<0.000 01]。治疗后低密度脂蛋白水平低于对照组[WMD=-0.53,95%CI(-0.87,-0.18),P=0.003]。各组不良反应发生率差异均无统计学意义[RR=2.25,95%CI(0.71,7.16),P=0.17]。结论脑心通联合他汀类药物治疗高脂血症疗效明显,对TC、TG、HDL-C、LDL-C的改善有效,联合阿托伐他汀钙对TC改善的疗效较为确切,不良反应发生率未见与其他药物有明显差异,推荐临床联合应用,并建议补充更多高质量的相关研究。
OBJECTIVE To evaluate the efficacy and safety of Naoxintong capsule combined with statins in treating hyperlipidemia. METHODS We searched the Cochrane library, Pub Med, Embase, Medline, CNKI, CBM, VIP and Wanfang database for RCTs, and analized by Revman 5.3 software. RESULTS Fourteen RCTs, a total of 1 244 subjects were included. Compared with the statins alone, the total effect of lipid of Naoxintong capsule combined with statins was higher than that in control group [RR=1.20, 95%CI（1.10, 1.31）, P〈0.000 1], the TC level after treatment of Naoxintong capsule combined with statins was lower than that in control group [WMD=-0.79, 95%CI（-1.06,-0.53）, P〈0.000 01], the heterogeneity of subgroup of Naoxintong capsule combined with Atorvastatin Calcium was low（P=0.09, I2=48%）. The TG level after treatment of combined group was lower than control group [WMD=-0.68, 95%CI（-0.92,-0.45）, P〈0.000 01], the HDL-C level after treatment of combined group was higher than control group [WMD=0.28, 95%CI（0.18, 0.37）, P=0〈0.000 01], the LDL-C level after treatment of combined group was lower than that in control group [WMD=-0.53, 95%CI（-0.87,-0.18）, P=0.003]. The incidence of adverse reactions in each group showed no significant difference [RR=2.25,95%CI（0.71,7.16）,P=0.17]. CONCLUSION Naoxintong capsule combined with statins may more effectively improve hyperlipidemia, including TC, TG, HDL-C and LDL-C, the efficiency of combined with statins for TC is exactly and there is no significant difference of adverse reactions compared with other drugs, this article recommend it used in the treatment of hyperlipidemia in clinical and to add more high quality researches.
作者
师帅
褚瑜光
张丽梅
邱志凌
汪九重
胡元会
纪鑫毓
SHI Shuai;CHU Yuguang;ZHANG Limei;QIU Zhiling;WANG Jiuchong;HU Yuanhui;JI Xinyu(Guang＇anmen Hospital, China Academy of Chinese Medical Science, Beijing 100053, China;Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150036, China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2018年第4期566-572,共7页
Chinese Journal of Modern Applied Pharmacy
